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abstract
PURPOSE Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of
treatment after becoming refractory to standard therapies. Duvelisib was approved by the Food and Drug
Administration for relapsed or refractory (RR) chronic lymphocytic leukemia or small lymphocytic lymphoma
(SLL) and RR follicular lymphoma (FL) after two or more prior systemic therapies. On the basis of the activity of
duvelisib, a ﬁrst-in-class oral dual inhibitor of phosphoinositide 3-kinase-d,-g, in RR iNHL in a phase I study, the
safety and efﬁcacy of duvelisib monotherapy was evaluated in iNHL refractory to rituximab and either che-
motherapy or radioimmunotherapy.
PATIENTS AND METHODS Eligible patients had measurable iNHL (FL, SLL, or marginal zone B-cell lymphoma)
double refractory to rituximab (monotherapy or in combination) and to either chemotherapy or radio-
immunotherapy. All were treated with duvelisib 25 mg orally twice daily in 28-day cycles until progression,
unacceptable toxicity, or death. The primary end point was overall response rate (ORR) using the revised
International Working Group criteria for malignant lymphoma.
RESULTS This open-label, global phase II trial enrolled 129 patients (median age, 65 years; median of three prior
lines of therapy) with an ORR of 47.3% (SLL, 67.9%; FL, 42.2%; MZL, 38.9%). The estimated median duration
of response was 10 months, and the estimated median progression-free survival was 9.5 months. The most
frequent any-grade treatment-emergent adverse events (TEAEs) were diarrhea (48.8%), nausea (29.5%),
neutropenia (28.7%), fatigue (27.9%), and cough (27.1%). Among the 88.4% of patients with at least one grade
3 or greater TEAE, themost common TEAEs were neutropenia (24.8%), diarrhea (14.7%), anemia (14.7%), and
thrombocytopenia (11.6%).
CONCLUSION In the DYNAMO study, oral duvelisib monotherapy demonstrated clinically meaningful activity and
a manageable safety proﬁle in heavily pretreated, double-refractory iNHL, consistent with previous observations.
Duvelisib may provide a new oral treatment option for this patient population of which many are elderly and in
need of additional therapies.
J Clin Oncol 37:912-922. © 2019 by American Society of Clinical Oncology
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INTRODUCTION
Non-Hodgkin lymphoma (NHL) is the ﬁfth most fre-
quent malignancy in Western countries, with an ex-
pected 74,680 patients being diagnosed in the United
States in 2018.1 Indolent NHL (iNHL) constitutes
approximately one third of NHLs, with follicular lym-
phoma (FL), the most common type, accounting for
20% to 30%.2 Other indolent subtypes include small
lymphocytic lymphoma (SLL) andmarginal zone B-cell
lymphoma (MZL, which includes nodal and splenic
marginal zone), which account for approximately 7%
and 4% of all NHLs, respectively.3 The disease course
for iNHL is variable, with some patients remaining
asymptomatic for extended periods and others re-
quiring immediate intervention.
For more than a decade, combinations of the anti-
CD20 monoclonal antibody rituximab with alkylator or
purine analog-based chemotherapy regimens (ie,
chemoimmunotherapy) have been the cornerstone
of frontline and relapsed iNHL therapy.4-8 With such
treatment, median progression-free survival (PFS) and
overall survival (OS) for FL are 6 to 8 and 12 to 15
years, respectively. However, the approximately 20%
of patients with FL treated with frontline rituximab
plus cyclophosphamide, doxorubicin, and prednisone
(R-CHOP) who progress within 2 years of initial di-
agnosis also have a lower 5-year OS rate (50%) than
patients without early progression (90%).9
Although outcomes are favorable for most patients, the
relapsing nature of indolent lymphomas necessitates
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serial retreatment, and advanced-stage disease re-
mains incurable, whichnecessitates lifelong manage-
ment.10 Despite recent drug approvals, alternative targeted
therapies remain the focus of clinical trials that address
disease resistance, which reduces options for patients with
multiple treatment failures.11
Phosphoinositide 3-kinase (PI3K) is a lipid kinase whose
catalytic subunit has four isoforms: a, b, g, and d. The
a- and b-isoforms are widely expressed in many tis-
sues; PI3K-g and PI3K-d are preferentially expressed in
hematopoietic cells12,13 and play predominantly non-
overlapping roles in (MZL, which includes nodal and
splenic), B-cell survival. Pathways mediated by PI3K-d
and PI3K-g are involved in cell growth, migration, dif-
ferentiation, and metabolism, all critical to the patho-
genesis and progression of B-cell malignancies.14,15 PI3K-
d inhibition targets malignant B-cell proliferation and
survival through blockade of tumor cell autonomous and
tumor microenvironment (TME)–mediated cytokine re-
ceptor signaling, whereas PI3K-g inhibition disrupts the
formation of the TME by inhibiting T-cell and macrophage
migration and macrophage polarization to a tumor-
supporting M2 phenotype.16-20 The TME is also impor-
tant in the development and maintenance of hematologic
malignancies, including iNHL.21 Thus, the cooperation of
PI3K-g and PI3K-d in the interplay between tumor cells
and the TME, and in the establishment/maintenance of
the TME, makes dual inhibition an attractive therapeutic
target.
Duvelisib, an oral dual inhibitor of PI3K-d and -g, was
approved by the US Food and Drug Administration (FDA)
in September 2018 for treatment of relapsed or refractory
(RR) chronic lymphocytic leukemia (CLL) or SLL after
two or more prior therapies and for RR FL after two or
more prior systemic therapies.22 Approval of 25 mg twice
daily was supported by phase I ﬁndings that plasma
exposure at higher doses did not further increase either
response rates or markers of PI3K-d inhibition; 25 mg
twice daily demonstrated clinical activity and an ac-
ceptable safety proﬁle in advanced hematologic malig-
nancies in IPI-145-02 (ClinicalTrials.gov identiﬁer:
NCT01476657).23 In that study, the overall response rate
(ORR) among 31 patients with RR iNHL treated with
duvelisib monotherapy was 58.1%, including six (19.4%)
complete responses (CRs).23,24
Duvelisib’s dual mechanism of PI3K-d,-g inhibition may
represent both a therapeutic advantage over selective
PI3K-d inhibitors and a new alternative for treating B-cell
malignancies. With consideration of the need for effec-
tive new therapies for chemoimmunotherapy-refractory
iNHL, the therapeutic value of duvelisib monotherapy in
this high-risk population became the focus of the
Duvelisib in Subjects With Refractory Indolent Non-
Hodgkin Lymphoma (DYNAMO) study and duvelisib’s
FDA approval.
PATIENTS AND METHODS
Study Design and Treatment
DYNAMO was a single-arm, phase II, open-label study of
the antitumor activity and safety of oral duvelisib mono-
therapy in patients with relapsed iNHL refractory to ritux-
imab (ie, no response or disease progression [PD] within
6 months after completion of therapy) and to either che-
motherapy or radioimmunotherapy (RIT). The study was
conducted at 56 sites across 12 countries in Europe,
Canada, and the United States. Institutional review boards
and/or ethics committees approved protocols at all sites.
Study conduct followed International Conference on Har-
monisation Guidelines for Good Clinical Practice, including
written informed consent from all patients and rigorous data
monitoring.
Oral duvelisib 25 mg twice daily was self-administered
continuously in 28-day cycles until PD, unacceptable
toxicity, or death. Up to two dose reductions for the same
treatment-emergent adverse event (TEAE) were permitted.
Prophylaxis for Pneumocystis jirovecii pneumonia (PJP),
herpes simplex virus (HSV), and herpes zoster virus (HZV)
was required.
The primary end point was ORR assessed by an in-
dependent review committee (IRC) and deﬁned as a CR or
partial response (PR) per revised International Working
Group (IWG) criteria.25 Secondary efﬁcacy end points in-
cluded duration of response (DOR), PFS, OS, and time to
response (TTR).
Patient Eligibility
Patients were 18 years of age or older with histologically
conﬁrmed FL, SLL, or MZL (splenic, nodal, and extranodal)
and radiologically measurable disease with a lymph node or
tumor mass greater than or equal to 1.5 cm in at least one
dimension. Patients with grade 3B FL or clinical evidence of
transformation to an aggressive lymphoma subtype were
excluded. Eligible patients had disease refractory (deﬁned
under Study Design and Treatment) to both rituximab
(monotherapy or in combination) and either chemotherapy
or RIT. At least one prior chemotherapy regimen (with or
without rituximab) must have contained an alkylating agent
or a purine analog. Patients were required to have an
Eastern Cooperative Oncology Group performance status of
0 to 2 and adequate renal (serum creatinine less than or
equal to two times the upper limit of normal [ULN]) and
hepatic function (total bilirubin less than or equal to one
and a half times ULN and aminotransferases less than or
equal to three times ULN). Key exclusion criteria were prior
PI3K or Bruton’s tyrosine kinase inhibitor therapy; prior,
current, or chronic viral infections (HIV, hepatitis B virus, or
hepatitis C virus); ongoing treatment with long-term im-
munosuppressants; and inability to receive PJP, HSV, or
HZV prophylaxis. There were no restrictions with regard to
cytopenias.
Journal of Clinical Oncology 913
Phase II Study of Oral Duvelisib in Refractory iNHL
Downloaded from ascopubs.org by UNIVERSITY LIVERPOOL on June 4, 2019 from 138.253.072.186
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
Study Assessments
Response was assessed at cycles 3, 5, 7, and 10 and every
four cycles thereafter until 2 years from the start of study
treatment. Response was based on revised IWG response
criteria for NHL using consistent imaging: computed to-
mography, positron emission tomography/computed to-
mography, or magnetic resonance imaging.25
Safety assessments included physical examinations, elec-
trocardiograms, and adverse event (AE) and clinical lab-
oratory monitoring. Severity of TEAEs and laboratory
abnormalities was graded using the National Cancer In-
stitute Common Terminology Criteria for Adverse Events
(version 4.03).26 An independent data monitoring com-
mittee reviewed all safety information. After treatment
discontinuation, survival data were collected every 6 months
for up to 3 years from treatment initiation.
Statistical Methods
Using a group sequential design with one interim analysis,
120 patients provided more than 90% power to test the
hypothesis of an ORR greater than or equal to 45% against
the null hypothesis of an ORR less than or equal to 30% at
a one-sided overall signiﬁcance level of .025. A P value
and a two-sided 95% exact CI for ORR were calculated
using the binomial distribution.
Best tumor response (CR, PR, stable disease, or PD) was
assessed for each patient. PFS was the time from ﬁrst
duvelisib dose to ﬁrst documentation of PD or any-cause
death. DOR was the time from ﬁrst documentation of best
response (CR or PR) to ﬁrst documentation of PD or any-
cause death. OS was the time from ﬁrst dose to date of
death, and TTR was the time from ﬁrst dose to ﬁrst doc-
umentation of response. The lymph node response rate
(greater than or equal to 50% reduction in the sum of the
product of the longest perpendicular dimensions of the
target lesion) also was calculated, and time-to-event end
points were calculated using the Kaplan-Meier method.
A formal futility interim analysis was conducted approxi-
mately 4 months after 30 patients initiated treatment,
and the independent data monitoring committee recom-
mended study continuation. The ﬁnal analysis was per-
formed after the last enrolled patient completed 6 months
of therapy or experienced PD; these data, with 2 additional
years of follow-up, are presented here, with an analysis
cutoff date of May 2018.
RESULTS
Patient Characteristics
From June 2013 to October 2015, 129 patients were
enrolled and received at least one dose of duvelisib. His-
tologic subtypes included FL (83 patients), SLL (28 pa-
tients), and MZL (18 patients). Patient characteristics are
listed in Table 1.
Most patients (68.2%) were male, 89.9% were white, and
the median age was 65 years (range, 30 to 90 years). Most
patients (85%) had advanced-stage (III or IV) iNHL, and
67% had elevated lactate dehydrogenase. Patients had
an Eastern Cooperative Oncology Group performance
status of 1 (94.6%) or 2 (5.4%) at enrollment. Among
patients with FL, 87%were intermediate or high risk per the
Follicular Lymphoma International Prognostic Index.
Patients had received a median of three (range, one to 18)
prior systemic anticancer regimens, and 52 patients (40%)
received four or more prior regimens. Nearly two thirds of
patients had prior bendamustine (82 patients [64%]).
Common prior regimens were rituximab plus bendamus-
tine (64 patients [50%]), R-CHOP (48 patients [37%]), and
rituximab plus cyclophosphamide and prednisone (38
patients [30%]). Six patients (5%) had prior autologous
stem-cell transplantation.
Nearly all patients had disease refractory to rituximab either
alone or in combination (127 patients [98%]), 119 patients
(92%) had disease refractory to an alkylating agent or
purine analog, and 117 patients (91%) had disease re-
fractory to combination therapy with rituximab and an
alkylating agent. Nearly all patients had disease refractory
to the most recent regimen (124 patients [96%]), and 95
patients (77%) had disease refractory to two or more reg-
imens. Among the 39 patients with FL who received an
R-CHOP (or equivalent) chemoimmunotherapy regimen as
ﬁrst therapy, 30 (77%) experienced early relapse (no
response during treatment or PD or time to next treatment
less than 2 years). No notable differences in demographics
were observed across lymphoma subtypes.
Disposition
Of 171 screened patients, 42 were excluded as a result
of screen failures, yielding 129 in the full analysis set. As
of the May 2018 data cutoff, ﬁve patients were still on
treatment. Of the 124 who discontinued treatment, ap-
proximately one half (66 patients [51.2%]) did so because
of PD; one fourth (31 patients [24%]) because of AEs; and
the remaining one fourth because of investigator decision,
death, patient withdrawal, or noncompliance. As of May
2018, 33 patients (25.6%) remained in the survival follow-
up (Appendix Fig A1, online only).
Efﬁcacy
Median follow-up time (from ﬁrst dose until last contact date
or death) was 32.1 months. Table 2 lists the primary and
secondary efﬁcacy end points on the basis of IRC and
investigator response assessment by disease subtype.
The ORR per IRC-assessed response was 47% (95% CI,
38% to 56%), which included almost exclusively PRs (59 v
two CRs). The study met the primary end point (P , .001
against the null hypothesis that ORR was less than or equal
to 30% per IRC). ORR per investigator response assess-
ment was 60% (Table 2), with differences per IRC between
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some subgroups (Fig 1). For example, ORR was numeri-
cally higher in US patients (46 patients; ORR, 59%) than in
non-US patients (83 patients; ORR, 41%). ORR was lower
in patients with prior bendamustine therapy (82 patients;
ORR, 39%) than in those without prior bendamustine
therapy (47 patients; ORR, 62%).
TABLE 1. Patient Demographics and Disease Characteristics
Characteristic No. (%)
No. of patients 129
Age, years
Median 65.0
Range 30-90
Race
White 116 (89.9)
Black 6 (4.7)
Asian 1 (0.8)
American Indian or Alaskan Native 1 (0.8)
Other 1 (0.8)
Unknown/Missing 4 (3.1)
Sex
Male 88 (68.2)
Female 41 (31.8)
Time since NHL diagnosis, months
Median 54.15
Range 3.9-324.0
Stage at entry
I-II 19 (14.7)
III-IV 109 (84.5)
Missing 1 (0.8)
ECOG performance status
0-1 122 (94.6)
2 7 (5.4)
Histologic subtype
Small lymphocytic 28 (21.7)
Marginal zone 18 (14.0)
Extranodal 9 (6.9)
Splenic 5 (3.8)
Nodal 4 (3.1)
Follicular 83 (64.3)
FLIPI risk category (score)
Low (0-1) 11 (13.3)
Intermediate (2) 17 (20.5)
High (. 2) 54 (65.1)
Missing 1 (1.2)
Elevated LDH at baseline
Yes 86 (66.7)
No 42 (32.6)
Missing 1 (0.8)
No. of prior anticancer regimens
Median 3.0
Range 1-18
(continued in next column)
TABLE 1. Patient Demographics and Disease Characteristics
(continued)
Characteristic No. (%)
Time since completion of last therapy, months
Median 3.5
Range 0-121
Prior therapy
Rituximab 129 (100)
Alkylating agent/purine analog 129 (100)
Alkylating agent 127 (98.4)
Combination of rituximab and alkylating agent 122 (94.6)
Bendamustine 82 (63.6)
Anthracycline 78 (60.5)
Rituximab + bendamustine 64 (49.6)
R-CHOP 48 (37.2)
Time since completion of last rituximab-containing
therapy, months
Median 5.9
Range 1-121
Time since completion of last alkylating agent/purine
analog therapy, months
Median 7.7
Range 1-141
Prior therapy to which the disease was refractory
Rituximab 127 (98.4)
Alkylating agent/purine analog 119 (92.2)
Alkylating agent 117 (90.7)
Bendamustine 66 (51.2)
Anthracycline 51 (39.5)
Combination of rituximab and alkylating agent 117 (90.7)
Rituximab + bendamustine 55 (42.6)
R-CHOP 36 (27.9)
R-CVP 34 (26.4)
Disease refractory to most recent regimen 124 (96.1)
Disease refractory to two or more regimens 99 (76.7)
Bulky disease* at baseline 51 (39.5)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FLIPI,
Follicular Lymphoma International Prognostic Index; LDH, lactate
dehydrogenase; NHL, non-Hodgkin’s lymphoma; R-CHOP, rituximab
plus cyclophosphamide, doxorubicin, vincristine, and prednisone;
R-CVP, rituximab plus cyclophosphamide, vincristine, and prednisone.
*Bulky disease is the longest diameter of nodal target lesion greater
than or equal to 5 cm.
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ORR per IRC was 42%, 68%, and 39% in FL, SLL, andMZL
subtypes, respectively (Table 2). Overall, 99 (83%) of 119
patients experienced reductions in lymph node tumor
burden (Fig 2).
Responses were rapid and durable. Median TTR was
1.87 months (range, 1.4 to 11.7 months), with 59% and
84% of patients responding by 2 and 4months, respectively.
Median DOR was 10 months (95% CI, 6.5 to 10.5 months;
Fig 3A), with estimated probabilities of remaining in response
at 6 and 12 months of 69% and 35%. Median PFS was
9.5 months (95% CI, 8.1 to 11.8 months; Fig 3B), with the
probability of surviving and being progression free at
6 months estimated at 62%. Median OS was 28.9 months
(95% CI, 21.4 months to not estimable; Fig 3C), and OS at
1 year was estimated at 77% (Table 2).
Safety
Median duration of treatment exposure was 6.7 months
(range, 0.4 to 45.5 months). Most patients started six or
more cycles of duvelisib (77 patients [59.7%]), and 42
patients (32.6%) started 12 or more cycles. TEAEs reported
in more than 10% of patients are listed in Table 3. Themost
frequent any-grade AEs were diarrhea (48.8%), nausea
(29.5%), neutropenia (28.7%), fatigue (27.9%), and
cough (27.1%). The most frequent grade 3 or greater AEs
were neutropenia (24.8%), diarrhea (14.7%), anemia
(14.7%), and thrombocytopenia (11.6%). Colitis and
pneumonitis were reported in 10 patients (7.8%) and six
patients (4.7%), respectively. Three patients experienced
the following serious opportunistic infections and re-
covered: bronchopulmonary aspergillosis, cytomegaloviral
pneumonia, and PJP in a patient prescribed sulfame-
thoxazole and trimethoprim prophylaxis on day 1. The most
frequent grade 3 or greater nonhematologic laboratory
TEAEs were elevated levels of serum lipase (7%), ALT
(5.4%), and AST (3.1%).
TABLE 2. Summary of Efﬁcacy in Full Analysis Set
Efﬁcacy
Response by
IRC,
No. (%)
Response by
Investigator,
No. (%)
All patients (N = 129)
ORR (CR + PR) 61 (47.3) 77 (59.7)
95% Exact binomial CI 38.4 to 56.3 50.7 to 68.2
Best response
CR 2 (1.6) 4 (3.1)
PR 59 (45.7) 73 (56.6)
SD 42 (32.6) 38 (29.5)
PD 18 (14.0) 8 (6.2)
Unknown 7 (5.4) 6 (4.7)
No evidence of disease* 1 (0.8) 0
Median DOR by IWG,
months
10.0 10.0
95% CI 6.3 to 10.5 6.5 to 12.5
Median PFS, months 9.5 10.0
95% CI 8.1 to 11.8 8.3 to 11.7
Median OS, months 28.9 —
95% CI 21.4 to NE —
Median TTR, months 1.87 1.87
Range 1.4-11.7 1.0-12.3
Follicular lymphoma (n = 83)
ORR (CR + PR) 35 (42.2) 44 (53.0)
95% Exact binomial CI 31.4 to 53.5 41.7 to 64.1
Best response
CR 1 (1.2) 2 (2.4)
PR 34 (41.0) 42 (50.6)
SD 29 (34.9) 28 (33.7)
PD 14 (16.9) 7 (8.4)
Unknown 5 (6.0) 4 (4.8)
Small lymphocytic lymphoma
(n = 28)
ORR (CR + PR) 19 (67.9) 24 (85.7)
95% Exact binomial CI 47.6 to 84.1 67.3 to 96.0
Best response
CR 0 1 (3.6)
PR 19 (67.9) 23 (82.1)
SD 4 (14.3) 3 (10.7)
PD 3 (10.7) 0
Unknown 1 (3.6) 1 (3.6)
No evidence of disease* 1 (3.6) 0
Marginal zone B-cell lymphoma
(n = 18)
ORR (CR + PR) 7 (38.9) 9 (50.0)
95% Exact binomial CI 17.3 to 64.3 26.0 to 74.0
(continued in next column)
TABLE 2. Summary of Efﬁcacy in Full Analysis Set (continued)
Efﬁcacy
Response by
IRC,
No. (%)
Response by
Investigator,
No. (%)
Best response
CR 1 (5.6) 1 (5.6)
PR 6 (33.3) 8 (44.4)
SD 9 (50.0) 7 (38.9)
PD 1 (5.6) 1 (5.6)
Unknown 1 (5.6) 1 (5.6)
Abbreviations: CR, complete response; DOR, duration of response;
IRC, independent review committee; IWG, International Working
Group; NE, not estimable; ORR, overall response rate; OS, overall
survival; PD, disease progression; PFS, progression-free survival; PR,
partial response; SD, stable disease; TTR, time to response.
*No evidence of disease at baseline and no postbaseline
assessment of PD in one patient with a single extranodal target lesion
(nasopharynx) evaluated as CR by the investigator.
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Forty patients (31%) discontinued duvelisib as a result of
a TEAE. The only TEAEs that led to discontinuation in
more than one patient were pneumonitis (four patients
[3.1%]); pneumonia, colitis, and diarrhea (three patients
[2.3%] each); and generalized rash (two patients
[1.6%]). TEAEs were managed with dose interruption or
reduction in 85 patients (66%). Doses were reduced in
25 patients (19.4%), four (3.1%) of whom subsequently
increased their dose as allowed per protocol. Dose re-
ductions occurred most commonly with diarrhea (nine
0.0 0.2 0.4 0.6 0.8 1.0
Overall Response Rate (95% CI)
No. of
Patients
Subgroup
129 0.47 (0.38 to 0.56)Overall
83
28
18
0.42 (0.31 to 0.54)
0.68 (0.48 to 0.84)
0.39 (0.17 to 0.64)
Disease subtype
   FL
   SLL
   MZL
48
81
17
112
0.52 (0.37 to 0.67)
0.44 (0.33 to 0.56)
0.59 (0.33 to 0.82)
0.46 (0.36 to 0.55)
No. of prior therapies
   < 3
 3
   1
   > 1
82
47
0.39 (0.28 to 0.50)
0.62 (0.46 to 0.76)
Prior treatment with bendamustine
   Yes
   No
66
16
0.38 (0.26 to 0.51)
0.44 (0.20 to 0.70)
Refractory to bendamustine
   Yes
   No
64
65
0.41 (0.29 to 0.54)
0.54 (0.41 to 0.66)
Prior treatment with bendamustine + rituximab
   Yes
   No
55
9
0.40 (0.27 to 0.54)
0.44 (0.14 to 0.79)
Refractory to bendamustine + rituximab
   Yes
   No
124
5
0.48 (0.39 to 0.57)
0.40 (0.05 to 0.85)
Refractory to last therapy
   Yes
   No
37
92
0.41 (0.25 to 0.58)
0.50 (0.39 to 0.61)
Last therapy contains bendamustine
and is refractory
   Yes
   No
51
67
0.51 (0.37 to 0.65)
0.48 (0.35 to 0.60)
Bulky status (baseline lesion  5 cm)
   Yes
   No
88
41
0.49 (0.38 to 0.60)
0.44 (0.29 to 0.60)
Sex
   Male
   Female
64
65
0.52 (0.39 to 0.64)
0.43 (0.31 to 0.56)
Age, years
   < 65
 65
116
11
0.47 (0.37 to 0.56)
0.46 (0.17 to 0.77)
Race
   White
   Nonwhite
46
83
0.59 (0.43 to 0.73)
0.41 (0.30 to 0.52)
Region
   United States
   Outside United States
FIG 1. Subgroup analysis of overall response rate (ORR) per independent review committee (full analysis set). FL, follicular lymphoma; MZL, marginal zone
B-cell lymphoma; SLL, small lymphocytic lymphoma.
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patients [7.0%]) followed by febrile neutropenia
and lipase increases (three patients [2.3%] each).
No clinically meaningful safety differences were ob-
served among lymphoma subtypes (FL, SLL, and
MZL).
Seventeen deaths (13.2%) occurred on treatment (within
30 days of the last dose of duvelisib). Nine (7%) were
attributed to PD. Of the remaining eight, three (2.3%) were
deemed unrelated to treatment: a 61-year-old female with
cardiac and respiratory, thoracic, and mediastinal disor-
ders died as a result of cardiopulmonary arrest and re-
spiratory failure; a 79-year-old patient with ongoing
cardiopulmonary disease died as a result of cardiac
failure; and a 62-year-old patient with diabetes and car-
diopulmonary and thrombotic disease died as a result of a
scrotal phlegmon. Five deaths (3.9%) were considered
treatment related: a 90-year-old man developed fatal
pancolitis, an 82-year-old man experienced a fatal sus-
pected viral infection after approximately 8 months of
treatment, and an 83-year-old man with baseline grade 4
neutropenia and thrombocytopenia experienced fatal
septic shock after only 21 days of treatment. The
remaining two deaths were from severe skin toxicity as a
result of drug reaction with eosinophilia and systemic
symptoms syndrome and toxic epidermal necrolysis.
However, both events were confounded by concomitant
administration of medications associated with severe and
fatal drug reaction with eosinophilia and systemic
symptoms syndrome and toxic epidermal necrolysis.
One additional treatment-related death as a result of
pneumonia occurred approximately 36 days after the last
dose of duvelisib.
DISCUSSION
Although most patients with iNHL initially respond to
chemoimmunotherapy and experience long periods of
remission, virtually all will eventually progress or develop
recurrent disease.27,28 Despite several approved options for
relapsed iNHL, cumulative toxicities from multiple thera-
pies and resistance or transformation to high-grade or
aggressive lymphomas remain major challenges.29,30 With
few patients eligible for potentially curative allogeneic stem-
cell transplantation, new therapies are needed.
The DYNAMO study evaluated the safety and efﬁcacy of
oral duvelisib monotherapy in patients whose disease had
become refractory to standard therapies and, therefore,
represent the greatest unmet need. Among a heavily
pretreated and high-risk iNHL study population, the ORR
was 47% (two CRs, 59 PRs), and lymph node disease was
reduced in 83% of patients. Responses generally occurred
within the ﬁrst 2 months of therapy and were durable
(median DOR, 10 months).
The safety proﬁle was similar across lymphoma subtypes
and consistent with that observed in the phase I IPI-145-02
study.23,24 AEs were generally low grade and manageable
with protocol-speciﬁed risk mitigation measures, including
dose reductions/interruptions (70% of patients). Similar
to observations with other PI3K inhibitor and immuno-
oncology therapies,30,31 immune-related toxicities,
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including pneumonitis, transaminase elevations, colitis,
and rash, were observed, requiring treatment discontin-
uation in 31% of patients. Prophylaxis for PJP, HSV, and
HZV infections was required per protocol. Serious op-
portunistic infections occurred in less than 5% of patients
and were not associated with fatal outcomes.
The efﬁcacy demonstrated by duvelisib monotherapy is
clinically meaningful, considering that nearly all patients
had disease refractory to prior rituximab and chemother-
apy, including the most recent prior therapy. Most patients
(approximately 75%) experienced early relapse (no re-
sponse on treatment or PD or time to next treatment less
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than 2 years) after their ﬁrst treatment regimen. Among
patients with FL, 27 (33%) experienced early progression
(less than 2 years after initial diagnosis) after frontline
R-CHOP (or equivalent) therapy and represent a population
with substantially poorer OS.9 This extent of treatment re-
fractoriness and the prevalence of other high-risk clinical
features (eg, high Follicular Lymphoma International
Prognostic Index risk and elevated lactate dehydrogenase)
distinguish a more difﬁcult-to-treat study population. An
examination of efﬁcacy in the subgroup of patients with FL
who received R-CHOP (or the equivalent) as their ﬁrst
therapy and experienced early relapse (as deﬁned in
Discussion) showed an ORR of 33%, median DOR of
12.6 months, and median PFS of 8.2 months.
With the recent FDA approval of duvelisib, there are now
several different treatment options for patients who have
received two or more prior therapies: in addition to duve-
lisib, the PI3K inhibitors copanlisib (intravenous inhibitor of
PI3K-a,-d) and idelalisib (oral inhibitor of PI3K-d). Although
these three new treatment options are important for both
physicians and patients, evaluating them side by side for
the treatment of FL is challenging because cross-trial
comparisons are undermined by variability in patient se-
lection and treatments. For instance, in the phase II
CHRONOS-1 study, copanlisib demonstrated an ORR of
59%. Although prior rituximab and alkylator therapy was
required, only 56% and 42% of patients had disease that
was refractory to rituximab and an alkylating agent, re-
spectively.32 In addition, the AE proﬁle of copanlisib,
speciﬁcally including hyperglycemic effects mediated
through PI3K-a isoform inhibition33,34 and hypertension,
merits consideration before use in an elderly patient
population with a high prevalence of these comorbidities. In
a phase II trial in patients with disease refractory to both
rituximab and chemotherapy, idelalisib demonstrated an
ORR of 57%.35 The AE proﬁle was similar to duvelisib,
except for a higher incidence of grade 3 or higher ami-
notransferase increase with idelalisib (13% v 5.4%). Al-
though many new therapies are being investigated for
patients with RR indolent lymphoma (lenalidomide and
rituximab, cellular therapies, bispeciﬁc antibodies, and
other small molecules), treatment options beyond the
PI3K inhibitors are still limited. RIT rarely is used, and one
of the two FDA-approved therapies was withdrawn from
the market for lack of use. The cumulative toxicities and
decreasing efﬁcacy of repeating cytotoxic chemotherapy,
even combined with a different CD20 antibody like obi-
nutuzumab, does not make this an attractive choice
either.
The combination of obinutuzumab and bendamustine was
recently approved for patients with FL who relapsed after or
whose disease proved refractory to a rituximab-containing
regimen on the basis of the results of the GADOLIN
(Efﬁcacy and Safety of Bendamustine Compared With
Bendamustine + Obinutuzumab [GA101] in Rituximab-
Refractory, Indolent Non-Hodgkin Lymphoma) study.36
Given that the bendamustine and rituximab regimen is
increasingly used as ﬁrst-line treatment of FL in the United
States, duvelisib monotherapy may offer an alternative for
the considerable number of patients whose disease is re-
fractory to bendamustine or who are unable to tolerate
bendamustine. Patients previously treated with bend-
amustine had an ORR of 39% per IRC. Although this was
nominally lower than what was seen in patients not pre-
viously exposed to bendamustine, it nevertheless suggests
that duvelisib has clinical activity for a population not ap-
propriate for treatment with bendamustine therapy.
Despite recent therapeutic advances, iNHL remains
largely incurable, with treatment resistance and cumu-
lative toxicity limiting options for many patients. Older
patients, whose comorbidities may preclude aggressive
TABLE 3. All-Grade TEAEs (. 10%) or Grade 3 or Greater TEAEs (. 5%) in the Full
Analysis Set
TEAE All Grades, No. (%) Grade ‡ 3, No. (%)
No. of patients 129 129
Patients with at least one TEAE 128 (99.2) 114 (88.4)
Diarrhea 63 (48.8) 19 (14.7)
Nausea 38 (29.5) 2 (1.6)
Neutropenia 37 (28.7) 32 (24.8)
Fatigue 36 (27.9) 6 (4.7)
Cough 35 (27.1) 0
Anemia 34 (26.4) 19 (14.7)
Pyrexia 32 (24.8) 0
Rash 24 (18.6) 6 (4.7)
Thrombocytopenia 24 (18.6) 15 (11.6)
Vomiting 24 (18.6) 5 (3.9)
Decreased appetite 19 (14.7) 1 (0.8)
Headache 20 (15.5) 0
Edema peripheral 22 (17.1) 3 (2.3)
ALT increased 18 (14.0) 7 (5.4)
Back pain 17 (13.2) 1 (0.8)
Arthralgia 19 (14.7) 0
Abdominal pain 19 (14.7) 2 (1.6)
Hypokalemia 17 (13.2) 4 (3.1)
Constipation 15 (11.6) 0
Asthenia 15 (11.6) 3 (2.3)
AST increased 13 (10.1) 4 (3.1)
Night sweats 13 (10.1) 0
Febrile neutropenia 12 (9.3) 12 (9.3)
Lipase increased 12 (9.3) 9 (7.0)
Pneumonia 10 (7.8) 7 (5.4)
Colitis 10 (7.8) 7 (5.4)
Abbreviation: TEAE, treatment-emergent adverse event.
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treatment and for whom dependence on hospitals and
clinic visits for infusional therapies represents a signiﬁcant
challenge, are likely to beneﬁt greatly from oral mono-
therapy. The efﬁcacy and consistent, manageable safety
proﬁle of duvelisib demonstrated in the DYNAMO study
support its potential as a novel therapy for patients with
refractory iNHL who currently lack sufﬁcient treatment
options.
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APPENDIX
Patients screened
(N = 171)
Patients treated (FAS)
(n = 129)
Patients on treatment
(n = 5)
Patients in survival
follow-up
(n = 33; 25.6%)
Screen failures
(n = 42)
Discontinued treatment
(n = 124; 96.1%)
Reason for discontinuation
Progressive disease
AEs
Investigator decision
Death
Patient withdrawal
Protocol violation
Other
(n = 66; 51.2%)
(n = 31; 24.0%)
(n = 12; 9.3%)
(n = 7; 5.4%)
(n = 6; 4.7%)
(n = 1; 0.8%)
(n = 1; 0.8%)
Discontinued study
Reason for discontinuation
Death
Follow-up complete
Patient withdrawal
Lost to follow-up
Other
(n = 61; 47.3%)
(n = 15; 11.6%)
(n = 9; 7.0%)
(n = 3; 2.3%)
(n = 3; 2.3%)
(n = 91; 70.5%)
FIG A1. Overall patient distribution. Number of screen failures was
derived from interactive voice response system. AE, adverse event;
FAS, full analysis set.
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